antiviral and associated therapy living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID-19 mild to moderate

	COVID-19 mild to moderate
antiviral and associated therapy
azithromycin	COALITION I Covid-19 Brazil ... Espitia-Hernandez Rashad A ...
azvudine	Ren
bromhexine	Li T
chloroquine and derivatives
chloroquine	NCT04342650
hydroxychloroquine	Zhaowei Chen Kamran Coalition Covid-19 Brazil I ... NCT04333654 FACCT Trial Min HC-nCoV ... Dubee
doxycycline	Spoorthi
Ensitrelvir (XOCOVA)	Mukae - Phase 2a
favipiravir	NCT04542694 Holubar M IRCT20151227025726N14 // U07 Ruzhentsova T FACCT Trial Dabbous HM Shinkai Udwadia AVIFAVIR Solaymani-Dodaran Shenoy S
favipiravir plus interferon	Khamis
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine	Coalition Covid-19 Brazil I ...
ivermectin	Espitia-Hernandez Bukhari Khan Kirti Abd-Elsalam Soto-Becerra Babalola Krolewiecki Spoorthi RIVET-COV ... Ahmed Chachar I-TECH ... Glorial F Chaccour Mayer Shahbaznejad
ivermectin plus doxycycline	NCT04523831 ...
lopinavir/ritonavir	ELACOI ...
lopinavir/ritonavir, ribavirin and interferon beta-1b	Hung et al.
nitazoxanide	Fontanesi Rocco Silva
remdesivir	GS-US-540-5774, 5 days GS-US-540-5773 ... GS-US-540-5774, 10 days
sofosbuvir and ledipasvir	Nourian A
umifenovir (arbidol)	Yethindra ELACOI ...